Correlation of toxicity and efficacy with pharmacokinetics (PK) of pegylated liposomal doxorubicin (PLD) (Caelyx®)

被引：0
|
作者：
Marye J. Boers-Sonderen
Carla M. L. van Herpen
Winette T. A. van der Graaf
Ingrid M. E. Desar
Mirjam G. W. Arens- van der Logt
Yvo M. de Beer
Petronella B. Ottevanger
Nielka P. van Erp
机构：
[1] Radboud University Medical Centre,Department of Medical Oncology, 452
[2] Maastricht University Medical Centre+,Department of Clinical Pharmacy and Toxicology
[3] Maastricht University,School CAPHRI
[4] Maastricht University,Department of Toxicology
[5] Radboud University Medical Centre,Department of Clinical Pharmacy
来源：
Cancer Chemotherapy and Pharmacology | 2014年 / 74卷
关键词：
Pegylated liposomal doxorubicin; Pharmacokinetics; Pharmacodynamics; Progression-free survival; Toxicities;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：457 / 463
页数：6
相关论文
共 50 条
  • [31] Pegylated liposomal doxorubicin (PLD) with bevacizumab (B) in second-line treatment of ovarian cancer (OC): Pharmacokinetics (PK), safety, and preliminary outcome results
    Muggia, F. M.
    Boyd, L.
    Liebes, L.
    Downey, A.
    Muller, C.
    Pothuri, B.
    Blank, S.
    Rutledge, T.
    Fishman, D.
    Verschraegen, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [32] Cellular function of the mononuclear phagocyte system (MPS) as a phenotypic probe for pegylated liposomal doxorubicin (PLD) pharmacokinetics (PK) in patients with recurrent ovarian cancer.
    Caron, W. P.
    Lay, J. C.
    Fong, A. M.
    La-Beck, N. M.
    Newman, S. E.
    Clarke-Pearson, D. L.
    Brewster, W. R.
    Van Le, L.
    Bae-Jump, V. L.
    Gehrig, P. A.
    Zamboni, W.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [33] Combination of bevacizumab (A) and pegylated-liposomal doxorubicin (PLD) (PLD-A) in sarcoma (SAR).
    Haddad, P. A.
    Skubitz, K. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 533S - 533S
  • [34] A pegylated liposomal platform: Pharmacokinetics, pharmacodynamics, and toxicity in mice using doxorubicin as a model drug
    Lu, WL
    Qi, XR
    Zhang, Q
    Li, RY
    Wang, GL
    Zhang, RJ
    Wei, SL
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2004, 95 (03) : 381 - 389
  • [35] Efficacy and toxicity profile of pegylated liposomal doxorubicin in patients with advanced ovarian cancer
    Christine Mayer
    Janina Brucker
    Florian Schuetz
    Christoph Domschke
    Sarah Bechstein
    Jörg Heil
    Michael Golatta
    Markus Wallwiener
    Christof Sohn
    Andreas Schneeweiss
    Joachim Rom
    Archives of Gynecology and Obstetrics, 2016, 294 : 123 - 129
  • [36] Combined regimen of temozolomide and liposomal pegylated doxorubicin in glioblastoma:: Toxicity and efficacy -: An update
    Beier, D.
    Hau, P.
    Jauch, T.
    Beier, C.
    Gänbbauer, S.
    Glas, M.
    Koch, H.
    Wismeth, C.
    Steinbrecher, A.
    Bogdahn, U.
    NEURO-ONCOLOGY, 2006, 8 (04) : 347 - 348
  • [37] Efficacy and toxicity profile of pegylated liposomal doxorubicin in patients with advanced ovarian cancer
    Mayer, Christine
    Brucker, Janina
    Schuetz, Florian
    Domschke, Christoph
    Bechstein, Sarah
    Heil, Joerg
    Golatta, Michael
    Wallwiener, Markus
    Sohn, Christof
    Schneeweiss, Andreas
    Rom, Joachim
    ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 2016, 294 (01) : 123 - 129
  • [38] Pegylated liposomal doxorubicin (CAELYX®), administered intravenously at conventional dosages, penetrates into the brain.
    Czejka, M
    Braunsdorfer, M
    Strauch, S
    Dittrich, C
    CLINICAL CANCER RESEARCH, 1999, 5 : 3819S - 3819S
  • [39] Factors affecting the pharmacokinetics of pegylated liposomal doxorubicin in patients
    Ninh M. La-Beck
    Beth A. Zamboni
    Alberto Gabizon
    Hilary Schmeeda
    Michael Amantea
    Paola A. Gehrig
    William C. Zamboni
    Cancer Chemotherapy and Pharmacology, 2012, 69 : 43 - 50
  • [40] Factors affecting the pharmacokinetics of pegylated liposomal doxorubicin in patients
    La-Beck, Ninh M.
    Zamboni, Beth A.
    Gabizon, Alberto
    Schmeeda, Hilary
    Amantea, Michael
    Gehrig, Paola A.
    Zamboni, William C.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 69 (01) : 43 - 50
12345